MUMBAI (NewsRise) -- Lupin is tying up a string of licensing deals with global pharmaceutical companies as the Indian drugmaker seeks to boost revenue and pare costs amid regulatory issues and a slow pace of pick up in new launches in the U.S.
On Wednesday, Lupin signed a deal with Germany's Boehringer Ingelheim to license, develop, and sell a new drug for patients suffering from difficult-to-treat cancers such as those affecting pancreas, colon, lungs, and skin. As part of the deal, Lupin will get an upfront payment of $20 million and an additional $700 million based on successfully achieving certain milestones, it said in a statement.
